MetLife heads into its first-quarter results reveal — posted after the close on May 6 — with the stock having already climbed 13% in a month, shorts retreating, and the Street lined up bullishly despite a wave of target-price cuts.
The headline is a clean beat. Q1 adjusted EPS came in at $2.42 against a $2.27 consensus estimate, and revenues of $19.68 billion topped the $19.48 billion expectation. The profit jump was driven in part by strong Asia demand, according to early reports, a segment that has been a consistent growth engine for the insurer. The stock's 13% one-month rally into the print reflected rising confidence in that thesis. The question now shifts to what management says on the May 7 earnings call.
The positioning data reinforced the constructive tone heading into the number. Short interest has been in clear retreat — down roughly 6.5% over the past month to 1.85% of free float, a level that was never aggressive to begin with. After a brief spike to around 14 million shares short in mid-April, sellers have unwound steadily as the stock recovered. The ORTEX short score holds near 33 out of 100, well below the threshold that would flag meaningful conviction from bears. Borrowing costs confirm the picture: the cost to borrow runs at just 0.44% annualised, and availability remains loose — the borrow market for MET is wide open, with very little demand to squeeze supply. There is no tension in the lending market here.
Options tell a slightly more nuanced story, but not a bearish one. The put/call ratio is 1.43, which sounds elevated, but it sits almost exactly at its 20-day average of 1.46 — a z-score of just -0.27. Structurally, MET's options market always carries a heavy put bias; that's the natural shape of the book for a large-cap insurer. The ratio has actually declined sharply from the 1.72-1.76 range that dominated late March and early April, when macro volatility was at its peak. The drift lower in PCR over the past six weeks lines up precisely with the stock's recovery.
The analyst community has been broadly positive but has trimmed ambitions. B of A Securities cut its target from $103 to $99 in mid-April while holding its Buy rating; Mizuho and Wells Fargo made similar small reductions to $93 and $90 respectively, also keeping positive ratings. UBS bucked the trend, raising its target from $98 to $102 on April 9, keeping its Buy. The mean price target across the Street is $89.31 — roughly 12% above Wednesday's close of $79.90 — reflecting genuine upside even after the recent run. The PE sits at 7.8x, the price-to-book at 1.69x. These are not demanding multiples for a company that just beat on both lines. The 12-month forward EPS growth estimate ranks in the 92nd percentile of the ORTEX universe — almost a top-decile growth expectation, paired with value-grade multiples.
On insider activity, the read is routine rather than meaningful. On March 2, a cluster of executives — including CEO Michel Khalaf, CFO John McCallion, and several divisional heads — filed sales totalling roughly $3.3 million in aggregate. The trades at $73.24 were likely scheduled disposals tied to annual vesting, not conviction selling. The stock is now $6.66 higher than that exit price, and the net 90-day insider position was actually a modest positive $9.1 million, reflecting award grants outweighing open-market sales across the window. Nothing here changes the story.
Peer moves on the week were broadly supportive. PRU gained 3.5%, FG rose 3.8%, and CNO added 2.1%. MET's own 2.1% weekly advance tracked the sector, meaning the earnings beat was not priced as an outlier event relative to group — the whole insurance complex has been recovering from the April sell-off in tandem.
What to watch on the May 7 call: whether management provides any colour on the Asia revenue trajectory, how underwriting margins have held against macro uncertainty, and any update on capital return plans — given that the dividend data in the system is stale (last confirmed dividends date to mid-2022, and the current yield implied by the DPS/price ratio of ~3% suggests regular payments continue). The beat is in; the forward guidance and capital allocation message is now the variable that shapes how much of the 12% analyst upside the stock actually closes.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
